The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis

Huang, Yaqi; Wei, Siqi; Jiang, Nan; Zhang, Lijuan; Wang, Siyuan; Cao, Xiaona; Zhao, Yue; Wang, Peiguo

doi:10.1186/s12885-018-5136-5

Table 1 Characteristics of studies included for meta-analysis

From: The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis

Author	Year	Country	Subtype	Tumor stage	Sample size	Median Age(years)	Gender (M/F)	Treatment modality	Follow up (months)	Survival analysis	Cut-off value (g/dl)	Analysis	Quality^a
Osterlind, K [21]	1986	Denmark	SCLC	NR	778	NR	NR	Chemoradiotherapy	NR	OS	12	MV	6
Albain, K S [22]	1991	USA	NSCLC	NR	1925	NR	77%/23%	Chemotherapy	NR	OS	11	MV	5
Takigawa, N [23]	1996	Japan	NSCLC	Advanced	186	68	134/51	Chemoradiotherapy	NR	OS	11	MV	7
Wigren, T [24]	1997	Finland	NSCLC	Mix	502	65	459/43	Radiotherapy	48	OS	12.5	MV	6
Ohlhauser, C [25]	1997	Germany	NSCLC	Mix	456	65.5	391/65	Radiotherapy	NR	OS	12.7	MV	6
Jazieh, A R [26]	2000	USA	NSCLC	Early	454	67	410/44	Surgery	28	OS,EFS	10	MV	5
Rzyman, W [27]	2003	Poland	NSCLC	Mix	493	59.7	493/100	Surgery	NR	OS	12	MV	5
Bremnes, R M [28]	2003	Norway	SCLC	Limited: 214 Extensive: 222	436	64	280/156	Chemoradiotherapy	>60	OS	Male: 13 Female: 11.5	MV	5
Langendijk, H [29]	2003	Netherland	NSCLC	Mix	529	68	87%/13%	Radiotherapy	>24	OS	Continuous	MV	6
Tammemagi, C M [30]	2003	USA	LC	NR	NR	NR	NR	Mix	29.7	OS	NR	MV	5
Yovino, S [31]	2005	USA	NSCLC	Early	82	68	48/34	Surgery	20.8	OS,RFS	12	MV	7
Berardi, R [32]	2005	Italy	NSCLC	Mix	439	68	374/65	Surgery	27	OS	10	MV	7
Pradier, O [33]	2005	Germany	NSCLC	Advanced	56	NR	44/12	Radiotherapy	NR	OS	11.6	UV	7
Aoe, K [34]	2005	Japan	LC	Mix	611	64	482/129	NR	NR	OS	Male: 13 Female: 12	MV	7
Mohan, A [35]	2006	India	SCLC	Limited: 27.6% Extensive: 72.4%	76	54.9	84.2%/5.8%	Chemoradiotherapy	NR	OS	12.8	MV	5
Mandrekar, S J [36]	2006	USA	NSCLC	Advanced	1053	63.3	NR	NR	NR	OS, TTP	Male: 13.2 Female: 11.5	MV	5
Laurie, SA [37]	2006	Canada	SCLC	Limited	130	62	63/67	Chemoradiotherapy	NR	OS, PFS	10	MV	6
Paul, I [38]	2006	UK	NSCLC	Mix	42	68.1	35/7	Surgery	55.2	OS	Continuous	MV	6
Gauthier, I [39]	2007	Canada	NSCLC	Early	476	61.3	311/165	Chemotherapy Surgery	NR	OS	12	MV	5
Ademuyiwa, F O [40]	2007	India & USA	NSCLC	Advanced	2013	NR	134/69	Chemoradiotherapy	25.6	OS	Continuous	MV	6
Panagopoulos, ND [41]	2008	Greece	NSCLC	Mix	331	64	295/36	Surgery	27.2	OS	12	MV	7
Park, M J [42]	2008	Korean	NSCLC	NR	358	NR	NR	Chemotherapy	NR	OS	10	MV	5
Jacot, W [43]	2008	France	NSCLC	Mix	301	63	242/59	Mix	20.8	OS	11	MV	6
Florescu, M [44]	2008	Canada	NSCLC	Advanced	485	NR	313/72	Chemotherapy	NR	OS	Male: 13.6 Female: 12	MV	5
Stinchcombe, T E [45]	2009	USA	NSCLC	Advanced	331	NR	218/113	Chemoradiotherapy	88	OS	13	MV	6
Garrido, P [13]	2009	Spain	NSCLC	Advanced	139	NR	127/12	Chemoradiotherapy	23	OS	12	MV	6
Belbaraka, R [46]	2010	France	NSCLC	Advanced	45	58.5	30/15	Chemotherapy	NR	OS	Male: 11.5 Female: 13	MV	7
Qiu MZ [47]	2010	China	NSCLC	Mix	430	59	310/120	Mix	31	OS	11	UV	6
Ovcaricek, T [48]	2010	Slovenia	NSCLC	Mix	53	65	40/13	Chemotherapy	NR	PFS	Continuous	MV	6
Yi, S Y [49]	2011	Korea	NSCLC	Advanced	191	72	NR	Chemotherapy	NR	OS	12	MV	6
Castro, J G [50]	2011	Brazil	NSCLC	Advanced	142	63	95/47	Chemotherapy	NR	OS	12	UV	5
Kishida, Y [14]	2011	Japan	NSCLC	Advanced	86	65	72/14	Chemoradiotherapy	20	OS	12	UV	7
Janku, F [51]	2011	USA	NSCLC	Mix	85	62	51/34	Chemotherapy+ targeted	NR	OS	12	UV	5
Gioulbasanis, I [52]	2011	Greece	LC	NR	115	66	101/14	Chemotherapy	38.2	OS	Continuous	UV	7
Hsu C L [53]	2012	China	NSCLC	Advanced	144	39.1	70/74	Chemoradiotherapy	NR	OS	11	MV	6
Holgersson G [54]	2012	Sweden	NSCLC	Mix	833	NR	NR	Mix	NR	OS	11	MV	5
Ng T [55]	2012	USA	NSCLC	Early	361	NR	161/200	Surgery	48	OS, DFS	Male: 13 Female: 12	MV	7
Wu, C [56]	2012	China	SCLC	Extensive	200	NR	174/26	Chemoradiotherapy	NR	OS	NR	MV	6
Kiely, B E [57]	2013	Australia	NSCLC	Advanced	244	64	146/98	Chemotherapy	21	OS	12	UV	5
Tas, F [58]	2013	Turkey	LC	Mix	100	59	91/9	Chemotherapy	5	OS	12	UV	5
Qu, X [59]	2014	China	NSCLC	Mix	649	58.9	456/193	Surgery	43	OS, RFS	14.6	MV	6
Smith, M O [60]	2014	UK	NSCLC	Mix	563	68.5	305/258	Surgery	NR	OS	13.1	MV	5
Kacan, T [61]	2014	Turkey	NSCLC	Mix	299	61	270/29	Mix	NR	OS	12	MV	5
Strouse, C S [12]	2014	USA	NSCLC	Advanced	2845	NR	NR	Chemotherapy	NR	OS	NR	MV	5
Oguz, A [62]	2014	Turkey	NSCLC	Advanced	186	63	161/25	NR	NR	OS	Continuous	MV	5
Crvenkova, S [63]	2015	Republic of Macedonia	NSCLC	Advanced	85	58.2	75/10	Chemoradiotherapy	36	OS	12	UV	6
Wu, X Y [64]	2015	China	NSCLC	Advanced	186	NR	NR	Chemoradiotherapy	>36	OS	12	UV	6
Imai, H [65]	2015	Japan	NSCLC	Advanced	159	64	126/33	Radiotherapy	NR	OS	Continuous	MV	5
Xie, D [66]	2015	China	SCLC	Limited:555 Extensive: 383	938	68	500/438	Mix	10.8	OS	12	MV	6
Abazari M [67]	2015	Iran	LC	Mix	355	63.5	256/99	Mix	NR	OS	14	UV	5
Cata, J P [68]	2016	USA	NSCLC	Early	861	65.29	394/467	Surgery	108.28	OS, RFS	Male: 13 Female: 12	MV	6
Shaverdian, N [69]	2016	USA	NSCLC	Early	110	76	NR	radiotherapy	28.9	OS,DFS	12	MV	5
Lin, Y [11]	2016	China	NSCLC	Mix	69	56	54/15	Mix	NR	OS,DFS	Male: 12 Female: 11	MV	6
Park S [70]	2016	Korea	NSCLC	Mix	630	64	236/394	Chemotherapy	NR	OS, PFS	Male: 13 Female: 12	UV	5
Shaverdian, N [69]	2016	USA	NSCLC	Early	147	NR	NR	Radiotherapy	28.9	OS, DFS	Continuous	MV	6
Minami, S [71]	2016	Japan	NSCLC	Advanced	103	69.5	85/18	Chemotherapy	NR	OS	Continuous	MV	6
Lee S [72]	2017	Korea	NSCLC	Advanced	135	NR	78/57	Korean medicine	NR	OS	Male: 13 Female: 12	UV	5

Abbreviations: NSCLC non-small cell lung cancer, SCLC small cell lung cancer, LC lung cancer, M/F male/female, NR not reported, OS overall survival, DFS disease-free survival, RFS relapse-free survival, PFS progression-free survival, EFS event-free survival, TTP time to progression, MV multivariate, UV univariate
^aThe quality of studies was assessed by Newcastle-Ottawa scale

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us